Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
Date:2/15/2011

CRANBURY, N.J., Feb. 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its second quarter ended December 31, 2010.  Palatin reported a net loss of $1.1 million, or $(0.09) per basic and diluted share, for the quarter ended December 31, 2010, compared to net income of $4.5 million, or $0.42 per basic and diluted share, for the same period in 2009.  

The net loss for the quarter ended December 31, 2010, compared to net income for the same period last fiscal year, was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial collaboration agreements with AstraZeneca AB (AstraZeneca) as a result of the successful completion of the research collaboration portion of the agreements.

REVENUERevenues for the quarter ended December 31, 2010 were $1.0 million, consisting of $846,768 in grant revenue received under the Patient Protection and Affordable Care Act of 2010 and $195,408 in contract revenue pursuant to the collaboration agreement with AstraZeneca. For the quarter ended December 31, 2009, Palatin recognized $7.3 million of contract revenue under its collaboration agreement with AstraZeneca.

COSTS AND EXPENSESTotal operating expenses for the quarter ended December 31, 2010 were $2.9 million compared to $3.8 million for the comparable quarter of 2009.  The net decrease in operating expenses for the quarter was primarily due to Palatin's previously disclosed realignment of resources and reduction in staffing levels.

CASH POSITION / GOING CONCERNPalatin's cash, cash equivalents and investments were $3.7 million as of December 31, 2010, compared to $8.9 million at June 30, 2010, with current liabilities of $2.0 million as of December 31, 2010 compared to $2.4 million as of June 30, 2010.  Palatin's Quarterly Report on Form 10-Q, filed on February 14, 2011, contains going concern disclosures, as did Palatin's Annual Report on Form 10-K filed on September 27, 2010.

CONFERENCE CALL / WEBCAST Later this week Palatin will announce the time and date of a conference call and webcast to discuss its second quarter of fiscal year 2011 financial results.

About Palatin Technologies, Inc. Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics.  Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements Statements about future expectations of Palatin Technologies, Inc., including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to Palatin's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release. PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations

(unaudited)Three Months Ended December 31,Six Months Ended December 31,2010200920102009REVENUES:License and contract$
95,408$
7,283,299$
411,555$
,945,918Grant846,768-846,768-Total revenues1,042,1767,283,2991,258,32310,945,918OPERATING EXPENSES:Research and development1,984,4402,712,8715,437,2025,382,435General and administrative889,4761,134,9632,271,2522,288,694Total operating expenses2,873,9163,847,8347,708,4547,671,129Income (loss) from operations(1,831,740)3,435,465(6,450,131)3,274,789OTHER INCOME (EXPENSE):Investment income32,98770,31753,362103,629Interest expense(1,329)(2,315)(3,633)(7,016)Gain on sale of securities60,389-60,389-Gain on sale of supplies and equipment1,800-1,80095,000Total other income, net93,84768,002111,918191,613Income (loss) before income taxes(1,737,893)3,503,467(6,338,213)3,466,402Income tax benefit637,391998,408637,391998,408NET INCOME (LOSS)$
(1,100,502)$
4,501,875$
(5,700,822)$
4,464,810Basic net income (loss) per common share$
(0.09)$
.42$
(0.48)$
.42Diluted net income (loss) per common share$
(0.09)$
.42$
(0.48)$
.42Weighted average number of common shares outstanding used in computing basic net income (loss) per common share11,839,3099,616,95411,785,4709,373,788Weighted average number of common shares outstanding used in computing diluted net income (loss) per common share11,839,3099,664,50711,785,4709,417,662PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Balance Sheets

(unaudited)December 31,2010June 30,2010ASSETSCurrent assets:  Cash and cash equivalents$
,731,615$
5,405,430  Available-for-sale investments1,952,6663,462,189  Accounts receivable-2,879  Prepaid expenses and other current assets245,024393,313Total current assets3,929,3059,263,811Property and equipment, net1,794,9702,388,365Restricted cash475,000475,000Other assets270,581261,701Total assets$
,469,856$
2,388,877LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:  Capital lease obligations$
20,708$
9,670  Accounts payable 502,125155,795  Accrued compensation564,887-  Unearned revenue132,090-  Accrued expenses823,9842,219,466Total current liabilities2,043,7942,394,931Capital lease obligations 3,66314,284Deferred rent391,314661,389Total liabilities2,438,7713,070,604Stockholders' equity:  Preferred stock of $.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares as of December 31, 2010 and June 30, 2010, respectively5050  Common stock of $.01 par value – authorized 40,000,000 shares; issued and outstanding 11,854,028 and 11,702,818 shares as of December 31, 2010 and June 30, 2010, respectively118,540117,028  Additional paid-in capital218,718,757218,236,723  Accumulated other comprehensive income68,738138,650  Accumulated deficit (214,875,000)(209,174,178)Total stockholders' equity4,031,0859,318,273Total liabilities and stockholders' equity$
,469,856$
2,388,877
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
2. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
3. Palatin Announces Strategic Realignment of Operations
4. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
6. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
8. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
9. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
Breaking Biology News(10 mins):